Ken Fisher’s Outlook Therapeutics OTLK Stock Holding History

Ken Fisher’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-624	Closed	-$13.6K	–	1198
2023 Q1	$13.6K	Buy	+624	New	+$14K	﹤0.01%	1043

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Ken Fisher's OTLK Position: Q2 2023 in Review

Ken Fisher sold out of Outlook Therapeutics (OTLK) in Q2 2023, closing a stake of 624 shares — an estimated $13.6K sold.

Ken Fisher first reported a position in OTLK in Q1 2023 and held it in 1 quarter. The position peaked at $13.6K in Q1 2023. 87 funds tracked by Wall St. Rank hold OTLK as of Q2 2023.

Ken Fisher reported no remaining Outlook Therapeutics position as of Q2 2023 after selling out during the quarter.
Ken Fisher sold 624 Outlook Therapeutics shares in Q2 2023, an estimated $13.6K.
Ken Fisher first reported a position in Outlook Therapeutics in Q1 2023 and held it in 1 quarter.
Ken Fisher's Outlook Therapeutics position peaked at $13.6K in Q1 2023.
87 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2023.

Based on Fisher Asset Management's 13F filing for Q2 2023, filed 8 Aug 2023.